Collaborative International Pesticides Analytical Council

German Progress Report, May 2012
The meetings of DAPA and DAPF are held as joint meetings together with the Swiss PAC (Plant Protection Chemistry, Agroscope Changins-Wädenswil (ACW), Wädenswil)

A. Particular Pesticides (DAPA)

570 Chlorfenapyr: The results of a CIPAC collaborative trial will be presented in Dublin, Fries, BASF

Toluene Development of a general method for the determination of toluene in formulations (still ongoing)

B. Physical Methods for formulations (DAPF)

Persistent foaming (MT 47.3) An amended method 47.3 for all formulation types that are applied with water will be presented Zindel, Bayer CropSciences

Tablets Disintegration of water soluble tablets: A CIPAC collaborative trial concerning the disintegration of water soluble tablets is in preparation:

Braunschweig, May 2012 R HÄNEL, A STEER & C VINKE
Annual CIPAC/FAO/WHO Report Form on the Quality Control of Pesticides

Country/Name and Address of the Institution (contact person):
Federal Republic of Germany
Federal Office of Consumer Protection and Food Safety (BVL)
Messeweg 11/12
38104 Braunschweig
Contact person: Astrid Besinger-Riedel; astrid.besinger-riedel@bvl.bund.de
Dr Claudia Vinke; claudia.vinke@bvl.bund.de

1 Essential Information

<table>
<thead>
<tr>
<th>Reporting period/year</th>
<th>Number of samples analysed</th>
<th>Number of non-compliance</th>
<th>Uses (optional)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>Authorisation samples</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>self-contained</td>
<td>82</td>
<td></td>
</tr>
<tr>
<td></td>
<td>authorisation:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>parallel import:</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Product monitoring</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>planned:</td>
<td>109</td>
<td></td>
</tr>
<tr>
<td></td>
<td>suspicion:</td>
<td>88</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Agricultural use: X</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Public Health use: -</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Home and Garden use: included in total, not recorded separately</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Other uses (please specify):</td>
</tr>
</tbody>
</table>

The reason of non-compliance:
**Authorisation samples**
self-contained: physical, chemical, technical properties (16)

**Product monitoring**
planned samples: active substance (quantitative)
suspicion samples: active substance (quantitative), impurities (quan.), formulators, physical, chemical, technical properties

2 CIPAC and other activities
Participation in the following trials:
MT 47.3 (DAPF)
Solution stability of tablets (CIPAC)
Disintegration of water soluble tablets (DAPF)
Chlorfenapyr (CIPAC)
Flutriafol (DAPA)

Successful participation in an AAPCO and an AFSCA collaborative trial.